Billionaire Izzy Englander Just Made a Big Bet on This Beaten-Down High-Yield Dividend Stock

Millennium Management increased its Bristol Myers Squibb stake by 5.8 million shares in Q1 2026, lifting holdings from 743,659 to 6,545,442 shares. The article is constructive on BMY, citing better-than-expected earnings, reiterated full-year guidance of $46B-$47.5B revenue and $6.05-$6.35 adjusted EPS, and a 4.6% forward dividend yield. However, near-term patent-expiration risk around Eliquis and Opdivo keeps the outlook mixed despite the fund’s bullish positioning.

Analysis

The interesting signal here is not the headline position increase itself, but the combination of size and timing: a large diversified fund is effectively expressing confidence that the market is still pricing BMY as if the next patent cliff is binary rather than managed. That matters because the stock is now in a valuation regime where downside is increasingly driven by multiple compression rather than earnings collapse, so any evidence of stabilization can create outsized rerating over a 3-6 month window.

The second-order beneficiary is less BMY’s peers than its own balance sheet. If management can preserve cash generation through lifecycle management, cost actions, and pipeline conversion, the dividend becomes a credible floor for long-only ownership and a source of forced demand from yield-oriented accounts. That said, the real overhang is not the next quarter; it is whether the market starts to believe the post-cliff earnings base can be defended beyond 12-18 months, because once that skepticism fades, short interest and underweight positioning can unwind quickly.

The contrarian angle is that consensus may be overestimating how much of the risk is already discounted. Low multiples often look cheap until the first estimate revisions hit, but in patent-exposed pharma, the stock can re-rate before fundamentals fully recover if management avoids negative surprises. The AI narrative is incremental rather than transformative, but it can matter as a margin-supporting lever; if it accelerates trial throughput even modestly, the market may assign more value to the pipeline than the current price implies.

Key reversal risks are straightforward: any erosion in Eliquis economics, slower-than-expected replacement of lost revenue, or guidance cuts would likely hit the stock over days to weeks, not years. The upside is a multi-quarter rerating if earnings stability holds and management continues to defend the dividend while showing pipeline execution.

Key Decisions for Investors

• Go long BMY on weakness over the next 2-6 weeks with a 6-12 month horizon; reward/risk improves if it stays below ~9x earnings while dividend support keeps value buyers involved.
• Use BMY Jan-2027 call spreads to express a rerating view; defined risk is preferable because the stock can remain range-bound until the market sees post-cliff revenue stability.
• Pair trade: long BMY / short a basket of higher-multiple large-cap pharma with less yield support; this captures relative de-risking if investors rotate toward balance-sheet-backed cash return stories.
• For event-driven desks, buy BMY only after any guidance-related pullback; the thesis is strongest when the market overreacts to near-term patent anxiety and offers a wider margin of safety.
• If you already own BMY, monetize part of the dividend carry by writing covered calls 1-2 quarters out; upside is likely more gradual than explosive unless the pipeline surprises positively.